The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis.
 
Stephanie L. Graff
Stock and Other Ownership Interests - HCA Healthcare
Honoraria - Academy for Continued Healthcare Learning; DAVA Oncology; IntegrityCE; Med IQ; Medical Educator Consortium; MedPage Today; MJH Life Sciences; Pfizer; WebMD/Medscape
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Seagen
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Lowell L. Hart
Honoraria - AstraZeneca; Circulogene Theranostics; Daiichi Sankyo; G1 Therapeutics; Karyopharm Therapeutics; Novartis; Seagen; Veracyte
Consulting or Advisory Role - Amgen; G1 Therapeutics; Genentech/Roche; Merck; Seagen
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Circulogene Theranostics; Genentech; Lilly; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Novartis (Inst); Seagen (Inst)
 
Pedram Razavi
Stock and Other Ownership Interests - Odyssey Biosciences
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Guardant Health; Inivata; Natera; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - Archer (Inst); AstraZeneca (Inst); AstraZeneca (Inst); bioTheranostics (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Illumina (Inst); Novartis (Inst); Tempus (Inst)
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Wolfgang Janni
Research Funding - Novartis
Other Relationship - Novartis
 
Lee S. Schwartzberg
Consulting or Advisory Role - Abbvie; AstraZeneca; BeyondSpring Pharmaceuticals; BMSi; Coherus Biosciences; Daiichi Sankyo; Epic Sciences; Foundation Medicine; Genentech; GlaxoSmithKline; Helsinn Therapeutics; Lilly; Mirati Therapeutics; Myriad Genetics; Napo Pharmaceuticals; Novartis; Pfizer; Sandoz; Sanofi; Seagen; Spectrum Pharmaceuticals
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Merck; Pfizer; Seagen
 
Brad Lanoue
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Tonatiuh Romero Salas
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Aamir Khakwani
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Courtney McDermott
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Purnima Pathak
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Ontada/McKesson; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Ontada/McKesson; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Seagen
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; GRAIL; Ipsen; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen